Equities

RLS Global AB

RLS:STO

RLS Global AB

Actions
  • Price (SEK)3.34
  • Today's Change0.03 / 0.91%
  • Shares traded5.31k
  • 1 Year change-27.07%
  • Beta0.7794
Data delayed at least 15 minutes, as of Sep 30 2022 17:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

RLS Global AB, formerly OraSolv Products AB, is a Sweden-based company engaged in the development of dental care products. It is primarily engaged in the development of biochemical products and methods for minimally invasive dentistry. The Company’s product portfolio includes Carisolv, a biochemical method for the removal of caries; Perisolv, product for the treatment of periodontitis; ChloraSolv, a treatment that cleanses and heals chronic wounds and Kindersolv, a caries treatment for children. The Company manufactures its products in the Sahlgrenska Science Park and sells them through distributors worldwide. The Company’s main shareholders are Rls Global Intressenter AB, Joki Invest AB, Zebra Holdings and Investments Limited.

  • Revenue in SEK (TTM)1.02m
  • Net income in SEK-24.46m
  • Incorporated2007
  • Employees--
  • Location
    RLS Global ABNeongatan 5 1TrMOELNDAL 43153SwedenSWE
  • Phone+46 31 784668246
  • Fax+46 317806821
  • Websitehttps://rls.global/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Corline Biomedical AB12.48m-3.34m184.39m8.00--2.00--14.78-0.1554-0.15540.58064.290.1252--8.71---3.35-12.45-3.55-13.80110.93240.81-26.77-273.49---3,340.000.00--91.0749.465.01--2.41--
Klaria Pharma Holding AB (publ)0.00-89.08m189.61m----3.37-----1.66-1.660.000.96550.00-------74.91-29.15-105.50-33.67-------2,713.74---30.590.00-------4.07------
Abliva AB133.00k-114.29m197.11m8.00--1.04--1,482.00-0.2717-0.27170.00030.180.0009--0.023916,625.00-72.81-67.30-82.45-79.05-----85,933.84-76,095.50---34.250.00---30.0960.91-105.86---43.06--
Saniona AB14.73m-444.71m198.39m24.00--2.07--13.46-7.13-7.130.23621.540.0381--4.56300,693.90-115.00-54.80-152.66-66.36-1,698.03-447.87-3,018.28-634.11---30.340.5044--27.81-32.53-459.58--12.71--
NextCell Pharma AB5.38m-30.47m198.71m----1.60--36.94-0.8863-0.88630.15653.610.0367--2.22---20.80-51.73-21.57-55.87-49.69-181.86-566.43-836.52----0.00--9.7437.05-38.89--110.26--
Scandion Oncology A/S-100.00bn-100.00bn201.27m----1.60----------3.09----------------------------0.0117-------217.81------
Lumito AB (publ)0.00-26.54m206.44m----1.58-----0.2176-0.21760.000.63180.00-------27.60-21.69-29.55-23.38------------0.00-------64.34------
Moberg Pharma AB (publ)0.00-16.17m208.27m----0.3757-----0.3304-0.33040.005.500.00-------3.22---3.31-------------124.410.0063--------------
Targovax ASA0.00-111.42m210.85m20.00--0.5583-----0.8083-0.80830.001.970.00----0.00-22.27-23.02-23.83-24.83-------21,183.60---62.210.1411---100.00--9.39------
Intellego Technologies AB14.85m-6.45m216.90m----17.84--14.60-0.3461-0.34610.83480.620.79752.435.17---34.63---40.42--75.43---43.43--2.80-160.740.043--22.70---220.86------
RLS Global AB1.02m-24.46m218.83m----24.62--215.60-0.3666-0.36660.01520.13320.0351--0.1113---84.58-48.17-118.13-56.91--34.51-2,409.36-1,175.260.6396-814.170.4406---68.04-25.6849.96------
Cereno Scientific AB0.00-19.36m229.46m----1.46-----0.1988-0.19880.001.500.00-------13.47-18.58-15.50-20.82-----------18.990.0326-------1.48--54.51--
Hamlet Pharma AB0.00-10.05m236.23m4.00--8.87-----0.0928-0.09280.000.37090.00-------37.15-78.57-45.89-95.01-----------32.450.00------67.05------
AlzeCure Pharma AB0.00-73.32m245.04m14.00--5.71-----1.76-1.760.000.84610.00----0.00-106.78---127.49--------------0.00-------8.99------
Lipidor AB15.27m-28.34m246.30m----10.37--16.13-0.9806-0.98060.53120.81940.3489--15.07---64.75---75.91-------185.59------0.00--2,380.00---31.39------
Data as of Sep 30 2022. Currency figures normalised to RLS Global AB's reporting currency: Swedish Krona SEK
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.